Dr Reddy's Labs launches Trientine Hydrochloride Capsules in US Market
Mumbai/UNI Pharma Major Dr Reddy's Laboratories on Friday announced the US launch of Trientine Hydrochloride Capsules a therapeutically equivalent generic version of Syprine (trientine hydrochloride) Capsules, approved by the US Food and Drug Administration (USFDA).
''We are pleased to provide this convenient alternative for patients, pharmacists and distribution partners," explained Marc Kikuchi, Chief Executive Officer and Head of Dr. Reddy's North America Generics.
"Our product can be stored at room temperature (20°C to 25°C or 68° F to 77°F) throughout the product shelf life of 24 months," the company said in a filing with BSE.
The Syprine brand and generic prududl had US sales or approximately USD94.2 million MAT for the most recent twelve months ending in December 2019 according to IMS Health.
Dr Reddy's Trientine Hydrochloride Capsules USP, 250 mg are available in 100 count bottles.
Syprine is a trademark of Alton Pharma.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
